Vendor Intelligence Report: Hybiopeptides

Published 3 Jul 2026. 26-page investigative report on who is behind Hybiopeptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 5 Finnrick lab tests, Hybiopeptides records 3 pass / 2 fail for a 60% overall pass rate. The lab signal is narrow: Tirzepatide is the more defensible of the two tested products, while Retatrutide is split and better treated as independently-test-or-avoid. Ratings also become less forgiving under stricter methodology.

The bigger issue is seller reliability. An Anabolex thread documents a buyer allegation involving a named @hybiopeptides.com sales persona, a $950 loss claim, and an empty-box/baby-powder substitution narrative. It is not a court finding, but moderator warnings, repeated persona spam, and unsupported Janoshik-tested purity claims make it material buyer-risk evidence.

Identity records add pressure. The storefront uses a prestige Hong Kong university address, but CUHK venue material does not support a conventional office there; completed registry checks did not resolve an accountable legal seller. Domain and archive records also do not substantiate the site’s older-history footer, and a sister-domain email invokes a real electronics company in a spoofing-like context.

The storefront is a 55-product inquiry-only catalog, with no public COAs, no public pricing, and no cart. A parallel zybiopeptides.com site shares key infrastructure and copied presentation, while the public sweep found little organic discussion and no visible X/web coupon network. The practical read is not a blanket quality verdict: the fraud, identity, and channel-control file dominates the modest test positives.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for both tested products
  • Dated domain, certificate-transparency, Wayback, DNS, hosting, and TLS chronology
  • CUHK address analysis, registry-check trail, and borrowed-company signal from the sister domain
  • Anabolex exhibits covering the $950 allegation, spam-email templates, and rotating sales personas
  • Hybiopeptides/zybiopeptides infrastructure comparison, catalog crawl, Janoshik search, and reputation sweep

Risk assessment

  • Fraud and shipment-substitution risk — high: Anabolex thread documents a $950 buyer allegation involving an empty box and reported baby-powder substitution, with moderators labeling Hybiopeptides a scammer/spam-and-steal source.
  • Identity and ownership spoofing risk — high: No verified legal entity or accountable officer; CUHK address is inconsistent with venue records; Shenzhen Zhiyou Technology name appears borrowed from an unrelated electronics company.
  • Official-channel and sister-domain confusion risk — high: zybiopeptides.com shares QQ Mail/XinCache infrastructure and copied site text; Hybiopeptides provides no canonical official-channel, authorized-reseller, COA-verification, or anti-counterfeit controls.
  • Unverifiable COA and Janoshik-claim risk — high: Product pages show no public COAs/batch data and the Janoshik public database returns zero hybiopeptides results despite spam claims of Janoshik-tested 99% purity.
  • Retatrutide quality-control risk — high: Finnrick shows Retatrutide at 77.68% across 2 tests with 1 pass and 1 fail; avoid or require independent lot testing.
  • Tirzepatide quality-control risk — medium: Finnrick shows Tirzepatide at 77.02% across 3 tests with 2 passes and 1 failure; better supported than Retatrutide but not a clean repeatability record.